









Markets
/
Stocks
/
nasdaq-fgen
/

FibroGen Inc

FGEN

View Detailed Chart

6.890USD

-0.100-1.45%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

27.85MMarket Cap

LossP/E TTM



FibroGen Inc

6.890

-0.100-1.45%

Overview Company Financials

Financials

Intraday

30m

Today

-1.45%

5 Days

-7.52%

1 Month

+22.82%

6 Months

+1348.70%

Year to Date

+1201.23%

1 Year

+1509.81%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 2 analysts

BUY

Current Rating

250.000

Target Price

3528.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

FibroGen Inc

FGEN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(2)

Buy(3)

Indicators

Sell(2)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.523

Neutral

RSI(14)

57.694

Neutral

STOCH(KDJ)(9,3,3)

11.150

Oversold

ATR(14)

0.440

Low Volatility

CCI(14)

-126.251

Sell

Williams %R

94.222

Oversold

TRIX(12,20)

1.866

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

7.046

Sell

MA10

7.273

Sell

MA20

7.133

Sell

MA50

4.397

Buy

MA100

2.360

Buy

MA200

1.399

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.

Ticker SymbolFGEN

CompanyFibroGen Inc

CEOMr. Thane Wettig

Websitehttps://www.fibrogen.com/